Rua Bioscience (RUA) H2 2025 earnings summary

Executive summary

• Achieved significant revenue growth in FY25, with sales momentum across Germany, Australia, and New Zealand, and established pipelines in the UK and Czechia.

• Loss before tax reduced to $3.46m from $13.72m in FY24, reflecting improved operational performance and cost control.

• Raised $1.5m from shareholders and secured a debt facility to support growth and working capital.

• Expanded product offerings and distribution partnerships in all key markets, leveraging regulatory changes and legacy genetics.

• Continued commitment to impact through Compassionate Access, scholarships, and sustainability initiatives.

Financial highlights

• Revenue from customers: $1.51m, up 1,661% year-over-year.

• Total revenue and other income: $1.9m, up 492% year-over-year.

• Loss before tax: $3.5m, improved by 75% year-over-year.

• Net assets: $4.9m; cash and investments: $241k as of 30 June 2025.

• Net tangible assets per share: $0.01 (down from $0.03 in FY24).

Outlook and guidance

• Focused on accelerating revenue growth, broadening product portfolio, and expanding international footprint in FY26.

• Plans further product launches in Germany, Australia, UK, and Czechia, and entry into additional emerging markets.

• Ongoing capital raising and operational improvements to achieve sustainable profitability.